.Pharmacolibrary.Drugs.ATC.N.N02CA01 .Pharmacolibrary.Drugs.ATC.N.N02CA01| name: | Dihydroergotamine | |
| ATC code: | N02CA01 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 1 | mg |
| volume of distribution: | 36 | L |
| clearance: | 1.5 | L/min |
| other parameters in model implementation | ||
Dihydroergotamine is an ergot alkaloid medication primarily used for the treatment of migraine headaches and cluster headaches. It acts as a vasoconstrictor of intracranial arteries, and as an agonist at serotonin (5-HT1) receptors. It is approved and still in use for acute migraine attacks by several regulatory agencies.
Pharmacokinetic parameters are reported in healthy adult volunteers following intravenous administration.
Shrewsbury, SB, et al., & Hoekman, J (2019). STOP 101: A Phase 1, Randomized, Open-Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision Olfactory Delivery (POD. Headache 59(3) 394–409. DOI:10.1111/head.13476 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30659611